A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK

Cost Effectiveness and Resource Allocation

Volumn 8, Issue , 2010, Pages

  Moore, Lee ^a   Remy, Vanessa ^b   Martin, Monique ^a   Beillat, Maud ^b   McGuire, Alistair ^c  

^a i3 Innovus   (United Kingdom)

^b SANOFI PASTEUR   (France)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FEMALE; HEALTH ECONOMICS; HEALTH STATUS; HERPES ZOSTER; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; NEURALGIA; PAIN ASSESSMENT; PROPHYLAXIS; UNITED KINGDOM;

EID: 77951527937     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-8-7     Document Type: Article

References (35)

1. Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. Rev Med Micro 1993, 4:222-230.
2. Stankus SJ, Dlugopolski M, Packer D. Management of Herpes Zoster (Shingles) and Postherpetic Neuralgia. American Family Physician 2000, 61:2437-2448.
3. Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract 2002, 19:471-475. 10.1093/fampra/19.5.471, 12356697.
4. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002, 18:350-354. 10.1097/00002508-200211000-00002, 12441828.
5. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of Herpes Zoster: a prospective population based study. Vaccine 2006, 24:1308-1314. 10.1016/j.vaccine.2005.09.026, 16352376.
6. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284. 10.1056/NEJMoa051016, 15930418.
7. Gilderman LI, Lawless JF, Nolen TM, Sterling T, Rutledge RZ, Fernsler DA, Azrolan N, Sutradhar SC, Wang WW, Chan IS, Schlienger K, Schödel F, Silber JL. Zostavax Protocol 010 Study Group: A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol 2008, 15:314-319. 10.1128/CVI.00310-07, 2238040, 18077611.
8. Van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009, 27:1454-67. 10.1016/j.vaccine.2008.12.024, 19135492.
9. Nagasako EM, Johnson RW, Griffin DR, Dworkin RH. Rash severity in herpes zoster: correlates and relationship to postherpetic neuralgia. J Am Acad Dermatol 2002, 46:834-839. 10.1067/mjd.2002.120924, 12063479.
10. Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia. BMJ 2000, 321:778-779. 10.1136/bmj.321.7264.778, 1118597, 11009498.
11. Gauthier A, Breuer J, Carrington D, Martin M, Remy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009, 137:38-47. 10.1017/S0950268808000678, 18466661.
12. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001, 19:3076-3090. 10.1016/S0264-410X(01)00044-5, 11312002.
13. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005, 6:356-363. 10.1016/j.jpain.2005.01.359, 15943957.
14. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ 2003, 326:748-750. 10.1136/bmj.326.7392.748, 1125653, 12676845.
15. Pellissier JM. Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Vaccine 2007, 25:8326-8337. 10.1016/j.vaccine.2007.09.066, 17980938.
16. Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004, 5:344-356. 10.1016/j.jpain.2004.06.001, 15336639.
17. Hospital Episodes Statistics Data 2004-2005. 2006, 7-4-2006., http://www.hesonline.nhs.uk
18. NHS Tariff 2005-2006. 2006, 7-4-2006., http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT_ID=4091529&chk=f%2Bcvh8
19. UK National Statistics. 2006, 7-4-2006., http://www.statistics.gov.uk
20. 2005 Annual Survey of Hours and Earnings (ASHE) Analysis by All Employees Table 1.5a. 2006, 7-4-2006., http://www.statistics.gov.uk/downloads/theme_labour/ASHE_2005/2005_all_employees.pdf
21. Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, Barben JL, Rarrick K, Stek JE, Chung MO, Schödel FP, Wang WW, Xu J, Chan IS, Silber JL, Schlienger K. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007, 55:1499-1507. 10.1111/j.1532-5415.2007.01397.x, 17908055.
22. Curtis L, Netten A. Unit Costs of Health and Social Care 2005. 2006. Personal Social Services Research Unit 2005. , http://www.erpho.org.uk/viewResource.aspx?id=13562
23. Health Survery for England 1996. 2006, 7-4-2006., http://www.archive.official-documents.co.uk/document/doh/survey96/ehch1.htm
24. Canada. National Population Health Survey (NPHS) 1996-1997. , http://www.statcan.gc.ca/dli-ild/data-donnees/ftp/nphs-ensp-eng.htm
25. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006, 10:127-135. 10.1016/j.ejpain.2005.01.014, 16310716.
26. Government Actuary's Department. 2006, 7-4-2006., http://www.gad.gov.uk
27. Bonneux L, Birnie E. The discount rate in the economic evaluation of prevention: a thought experiment. J Epidemiol Community Health 2001, 55:123-125. 10.1136/jech.55.2.123, 1731836, 11154251.
28. Bos JM, Postma MJ, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 2005, 23:639-649. 10.2165/00019053-200523070-00001, 16173156.
29. Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien B. Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J Clin Epidemiol 1998, 51:667-676. 10.1016/S0895-4356(98)00036-5, 9743315.
30. Brisson M. Cost-Effectiveness of Herpes Zoster Vaccine: Flawed Assumptions Regarding Efficacy against Postherpetic Neuralgia. Clinical Infectious Diseases 2007, 45:1527-1529. 10.1086/523011, 17990240.
31. National Institute for Clinical Excellence Guide to the methods of technology appraisal. London. 2004, National Institute for Clinical Excellence., http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf
32. Cohen DR, Henderson JB. Health, Prevention and Economics. 1988, Oxford, Oxford University Press.
33. Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 2005, 331:446-448. 10.1136/bmj.331.7514.446, 1188116, 16110075.
34. Gnann JW, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002, 347:340-346. 10.1056/NEJMcp013211, 12151472.
35. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000, 342:635-645. 10.1056/NEJM200003023420906, 10699164.